0
0
A new urine-based test developed by American researchers shows significant potential to detect prostate cancer with high accuracy, potentially reducing the need for painful and invasive prostate biopsies that are currently the standard for diagnosis. Developed through a collaborative study led by Johns Hopkins investigators and published recently in the peer-reviewed journal eBioMedicine, this noninvasive test detects specific biomarkers in urine to identify prostate cancer, marking an important advancement in cancer diagnostics.
Prostate cancer is the second leading cause of cancer deaths in men in the United States, making early and accurate detection critical for effective treatment and improved survival rates. Currently, diagnosis relies on prostate-specific antigen (PSA) blood tests followed by confirmatory biopsies where tissue samples are extracted using needles—a procedure that can be painful and carries risk of complications. This new urine test could transform prostate cancer screening by providing a less invasive and highly accurate alternative.
Key Findings and Test Performance
The research team identified three biomarkers—TTC3, H4C5, and EPCAM—that are present in the urine of men with prostate cancer. These markers derived from prostate tissue were found in samples collected before prostate removal surgery but were nearly absent after surgery, confirming their direct link to the cancerous tissue. The test was validated in development and validation groups achieving an accuracy rate of 91% in detecting prostate cancer and an 84% accuracy in correctly ruling it out.
An important strength of this test is its ability to detect prostate cancer even in cases where PSA levels are in the normal range. It also effectively distinguishes prostate cancer from other prostate conditions such as prostatitis (inflammation) and benign prostatic hyperplasia (enlarged prostate), both of which can cause elevated PSA but are noncancerous. This specificity can potentially reduce unnecessary biopsies and overtreatment associated with current PSA screening.
Expert Commentary
Dr. Ranjan Perera, Ph.D., director of the Center for RNA Biology at Johns Hopkins All Children’s Hospital and a senior author of the study, states, “This new biomarker panel offers a promising, sensitive, and specific, noninvasive diagnostic test for prostate cancer. It has the potential to reduce unnecessary biopsies and improve diagnostic accuracy in PSA-negative patients.”
Christian Pavlovich, M.D., a co-author and distinguished professor of Urologic Oncology at Johns Hopkins, adds, “There is a real need for non-PSA-based biomarkers for prostate cancer, and urine is quite easy to collect in the clinic. Most urologists feel that an accurate urinary biomarker would be a valuable addition to our current diagnostic armamentarium.”
Dr. Vipul Patel, director of urologic oncology at AdventHealth Cancer Institute and co-author, emphasized the potential clinical impact: “This test has the potential to help physicians improve the diagnostic accuracy of prostate cancer, reducing unnecessary interventions while allowing early treatment for those who need it. On behalf of physicians and patients globally, I advocate for further study and progress for these biomarkers.”
Context and Importance
Prostate cancer affects about 13 out of every 100 American men during their lifetime, according to the Centers for Disease Control and Prevention (CDC), with 2 to 3 of these men dying from the disease. While some prostate cancers grow slowly and may not require immediate intervention, others are aggressive and need timely treatment. Accurate diagnosis is therefore essential to balance the risks of overdiagnosis and overtreatment with the imperative for early detection and management of aggressive cancers.
The PSA test, while useful for initial screening, lacks specificity. Elevated PSA levels can arise from benign conditions, leading many men to undergo biopsies that may ultimately be unnecessary. Biopsies themselves carry risks including pain, bleeding, infection, and anxiety. A urine test that accurately detects prostate cancer biomarkers would be an important tool to refine patient selection for biopsy, sparing many men from these invasive procedures.
Limitations and Future Directions
Though promising, the urine test is currently in the research stage and will require further validation through larger clinical trials before becoming a routine diagnostic tool. Biomarker-based tests can vary in performance across diverse populations, and their implementation depends on standardization and regulatory approval.
Moreover, while the test shows high accuracy, no diagnostic method is perfect. False positives and negatives remain possible, which underscores the need for integrated clinical evaluation considering PSA levels, digital rectal exam findings, imaging results, and patient risk factors.
Implications for Public Health and Personal Decisions
If adopted widely, this urine-based biomarker test could reshape prostate cancer screening protocols, reduce patient burden from invasive biopsies, and improve early detection accuracy. For men, it may mean less anxiety, fewer medical complications, and more tailored treatment decisions.
Healthcare providers should stay informed of advances in biomarker diagnostics to guide patients effectively. Meanwhile, individuals concerned about prostate cancer risk should continue routine screening discussions with their healthcare professionals, considering family history, age, and other risk factors.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
- https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/new-urine-based-test-to-detect-prostate-cancer-could-replace-painful-biopsies/articleshow/123669480.cms
